bapineuzumab
E559467
Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
All labels observed (1)
| Label | Occurrences |
|---|---|
| bapineuzumab canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5981239 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: bapineuzumab Context triple: [Elan Pharmaceuticals, developed, bapineuzumab]
-
A.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
E.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: bapineuzumab Target entity description: Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
-
A.
Aduhelm
Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
-
B.
ocrelizumab
Ocrelizumab is a humanized monoclonal antibody used as a disease-modifying therapy for multiple sclerosis, particularly targeting CD20-positive B cells to reduce disease activity.
-
C.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
D.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
E.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
- F. None of above. chosen
Statements (37)
| Predicate | Object |
|---|---|
| instanceOf |
Alzheimer’s disease therapy candidate
ⓘ
investigational drug ⓘ monoclonal antibody ⓘ |
| actsOnPathway | amyloid cascade in Alzheimer’s disease ⓘ |
| administeredTo | patients with Alzheimer’s disease ⓘ |
| adverseEffect |
amyloid-related imaging abnormalities
ⓘ
microhemorrhage ⓘ vasogenic edema ⓘ |
| belongsToTherapeuticArea |
neurodegenerative diseases
ⓘ
neurology ⓘ |
| biologicType | IgG monoclonal antibody ⓘ |
| clinicalTrialPhase |
Phase II
ⓘ
Phase III ⓘ |
| developedFor | Alzheimer’s disease NERFINISHED ⓘ |
| developmentGoal | disease-modifying treatment for Alzheimer’s disease ⓘ |
| developmentStatus | clinical development discontinued ⓘ |
| drugClass | anti-amyloid monoclonal antibody ⓘ |
| hasEpitope | N-terminus of amyloid beta ⓘ |
| hasMolecularTarget | extracellular amyloid beta plaques ⓘ |
| indicationTestedIn |
mild Alzheimer’s disease
ⓘ
moderate Alzheimer’s disease ⓘ |
| intendedEffect |
reduce amyloid plaque burden
ⓘ
slow cognitive decline in Alzheimer’s disease ⓘ |
| isHumanizedFrom | mouse monoclonal antibody ⓘ |
| isInvestigatedIn | clinical trials for Alzheimer’s disease ⓘ |
| isNotApprovedFor | treatment of Alzheimer’s disease ⓘ |
| isParenteralDrug | true ⓘ |
| mechanismOfAction |
binds beta-amyloid plaques in the brain
ⓘ
promotes clearance of amyloid beta ⓘ |
| reasonForDiscontinuation | lack of efficacy in Phase III trials ⓘ |
| routeOfAdministration | intravenous ⓘ |
| target |
amyloid beta peptide
ⓘ
beta-amyloid NERFINISHED ⓘ |
| therapeuticApproach | passive immunization against amyloid beta ⓘ |
| therapyType | immunotherapy ⓘ |
| trialOutcome |
did not meet primary cognitive endpoints in Phase III
ⓘ
showed limited clinical benefit ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: bapineuzumab Description of subject: Bapineuzumab is a humanized monoclonal antibody that was investigated as an immunotherapy for Alzheimer’s disease by targeting beta-amyloid plaques.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.